Starling Oncology (STLNW) Operating Expenses (2020 - 2026)

Starling Oncology (STLNW) has reported Operating Expenses for 7 consecutive years, with $165.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses rose 26.63% year-over-year to $165.9 million; the trailing twelve-month figure through Jun 2026 stood at $613.3 million (up 30.14% YoY), and the FY2025 full-year result was $538.8 million, up 18.8% from the prior year.
• Operating Expenses grew to $165.9 million in Q2 2026 per STLNW's latest filing, from $154.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at $165.9 million in Q2 2026 and bottomed at $73.6 million in Q1 2022.
• Historically, Operating Expenses has averaged $113.8 million across 5 years, with a median of $112.4 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses jumped 56.29% in 2022, then grew 1.49% in 2025.
• Over 5 years, Operating Expenses stood at $96.5 million in 2022, then advanced by 4.74% to $101.1 million in 2023, then rose by 11.0% to $112.2 million in 2024, then jumped by 32.68% to $148.9 million in 2025, then rose by 11.44% to $165.9 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $165.9 million, $154.0 million, and $148.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.